Safety Study of PLX4032 in Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

July 31, 2015

Study Completion Date

February 29, 2016

Conditions
Malignant MelanomaColorectal Carcinoma
Interventions
DRUG

PLX4032

Oral capsules administered BID

Trial Locations (7)

3002

Peter MacCallum Cancer Centre, East Melbourne

10021

Memorial Sloan-Kettering Cancer Center, New York

19104

University of Pennsylvania, Philadelphia

37232

Vanderbilt Ingram Cancer Center, Nashville

77030

MD Anderson Cancer Center, Houston

90095

University of California Los Angeles, Los Angeles

Unknown

Royal Melbourne Hospital, Parkville

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

Plexxikon

INDUSTRY

NCT00405587 - Safety Study of PLX4032 in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter